The WHI study, explained honestly: what the numbers actually showed

The 2002 Women's Health Initiative (WHI) is the single study most responsible for how a generation of women came to fear hormone therapy. It was a large, rigorous, randomized trial — and its findings were real. But the way those findings were reported, in relative rather than absolute terms and applied to a cohort much older than the women who typically seek treatment, produced headlines far more alarming than the numbers warranted. This is an honest, source-by-source account of what the WHI actually showed, where the interpretation went wrong, and where expert guidance stands today.

What did the WHI actually find in 2002?

The most-publicized arm of the WHI randomized postmenopausal women to a combination of oral conjugated equine estrogens plus a synthetic progestin, or to placebo. In 2002, that arm was stopped early when investigators reported that the combination increased the risk of breast cancer, coronary heart disease events, stroke, and venous blood clots relative to placebo, while reducing fractures and colorectal cancer. Those directional findings were genuine. The problem was not the data; it was how the size of the risks was communicated to the public.

Relative risk vs absolute risk: why the headlines misled

The distinction between relative and absolute risk is the crux of the entire WHI misunderstanding. A relative risk describes how much a risk changes in proportion — 'a 26% increase' sounds enormous. An absolute risk describes how many additional real-world events that translates to in a given population over a given time. When a baseline event is rare, even a large relative increase can mean only a few extra cases per 10,000 women. The 2002 headlines led with the relative figures, stripped of the absolute context, which made small changes in uncommon events sound like a widespread danger.

The honest way to read any of these numbers is in absolute terms for a woman like you. A relative-risk headline tells you almost nothing about your personal odds without the baseline rate attached. This is the same principle that governs how risks are discussed in is hormone therapy safe: individual, absolute, and matched to your history — not a scary proportion detached from context.

How did the cohort's age skew the results?

The average WHI participant was roughly 63 years old, and many were more than a decade past their final period. That matters because the women who actually seek hormone therapy for symptoms are typically in their late 40s and early 50s, near the onset of menopause. Cardiovascular risk in particular behaves differently in a woman starting therapy at 52 than in one starting at 63 with more established arterial changes. Applying results from an older cohort directly to symptomatic women near menopause overstated the risks for the group most likely to be treated — a mismatch that later analyses made explicit.

What is the timing hypothesis?

The timing hypothesis is the idea, supported by later WHI age-stratified analyses and other studies, that the benefit-risk balance of hormone therapy depends heavily on how close to menopause it is started. Begun near the onset of menopause — within about 10 years, or before age 60 — the profile is considerably more favorable, particularly for cardiovascular outcomes, than when therapy is initiated many years later. It reframes the WHI not as proof that hormone therapy is dangerous, but as evidence that when and in whom it is started are decisive.

What do The Menopause Society and ACOG say now?

Current expert guidance reflects the fuller reading of the WHI rather than the 2002 headlines. Both The Menopause Society and ACOG support an individualized approach, and both identify a window — under 60 or within 10 years of menopause onset — in which the benefits of hormone therapy generally outweigh the risks for healthy, symptomatic women. This is a carefully bounded statement, not a blanket claim that hormone therapy is safe for everyone.

So the honest conclusion is neither 'the WHI was wrong' nor 'HRT is safe.' The WHI was a valid trial whose findings were widely misread, and the accurate takeaway is conditional: for the right candidate — a healthy woman with bothersome symptoms, started within 10 years of menopause or under 60 — the benefit-risk profile is favorable, and the decision belongs to her and a licensed clinician. Route matters too; see how transdermal and oral estrogen compare. Hormone therapy is not appropriate for everyone, and prescribing is never guaranteed.